Skip to content

Biomarker and IVD pipeline

Scailyte´s clinical focus is to develop diagnostic applications from single-cell data in oncology and women´s health by using cutting-edge analytical approaches.

InselSpital

Establishing a precision diagnostics portfolio

+ 6 new indications to be initiated in 2020/2021

Our portfolio

Cutaneous T-cell lymphoma

First disease biomarker clinically validated: our trained AI demonstrated unprecedented accuracy in a blinded study

THE PROBLEM

Cutaneous T cell lymphoma (CTCL) is a rare and severe skin cancer. In its initial stages CTCL shares similar symptoms to highly prevalent skin conditions such as atopic dermatitis (AD). Currently there is a lack of a definitive diagnostic test for CTCLs which means the disease is typically identified in advanced stages, once the patient’s immune system is compromised, or worse: altogether misdiagnosed. For the most aggressive form of CTCL, Sezary Syndrome, the 5 year survival rate is between 20–27%.

Collect data
single-cell data from cancer patients, atopic dermatits patients and healthy donors
Analyze data
user AI to discover disease-related patterns (AI training)
Define biomarker
Identify molecular profile or disease-related cell populations
Validate biomarker
Predict status of blinded samples by using the trained AI models
Collect data
single-cell data from cancer patients, atopic dermatits patients and healthy donors
Analyze data
user AI to discover disease-related patterns (AI training)
Define biomarker
Identify molecular profile or disease-related cell populations
Validate biomarker
Predict status of blinded samples by using the trained AI models
OUR SOLUTION

Scailyte is facing this challenge through the development of a precise and predictive diagnostic test. Using our proprietary AI driven cell analytics pipeline we identified CTCL- specific biomarkers that accurately diagnose CTCL with >90% specificity and sensitivity. This new diagnostic test will facilitate timely intervention, improve patient quality of life, dramatically reduce the treatment costs and ultimately save patient lives.

Making groundbreaking discoveries require collaborations and joint-ventures.